Susquehanna Increases Valeant Pharmaceuticals Int Price Target to $170.00
BVF has been the subject of a number of other recent research reports. Analysts at BMO Capital Markets raised their price target on shares of Valeant Pharmaceuticals Int from $162.00 to $164.00 in a research note on Friday, February 28th.
Trending on the Topix Network
Thu Mar 06, 2014
Valeant Pharmaceuticals International Donates $250,000 To The
The donation is a reflection of Valeant's ongoing support and commitment to the wellbeing of women, and is the first of four checks the company will present to NCADV in a one year period for a combined donation goal of "NCADV is thrilled to be working with Valeant as a partner in our efforts to end violence in the home," said , Executive Director ... (more)
Tue Mar 04, 2014
Valeant Pharmaceuticals Intl Price Target Raised to $158.00 at RBC Capital
The firm currently has an "outperform" rating on the stock. RBC Capital's target price points to a potential upside of 10.20% from the company's current price.
Fri Feb 28, 2014
Ubs Ag Increases Valeant Pharmaceuticals Intl Price Target to $170.00
The firm currently has a "buy" rating on the stock. UBS AG's price objective would indicate a potential upside of 14.86% from the stock's previous close.
Thu Feb 27, 2014
Canada Stocks-TSX opens higher as Valeant, TD drive gains
Canada's main stock index opened higher on Thursday, supported by gains in Valeant Pharmaceuticals International Inc and Toronto Dominion Bank after the companies reported quarterly results.
Nanaimo Daily News
Valeant Pharmaceuticals nets $124 million in Q4, or 36 cents per diluted share
Valeant Pharmaceuticals International Inc. is reporting net income of $124 million for the fourth quarter of 2013, or 36 cents per diluted share.
Tue Feb 25, 2014
Canada Stocks Top Among Biggest Markets on Gold Surge
Canadian stocks are beating the world's biggest markets this year, as a surge among gold miners propels the benchmark equity gauge toward a five-year high.
Mon Feb 24, 2014
Nehal Chopra's Ratan Capital is Betting on These Stocks
Nehal Chopra is a graduate from the Wharton School of the University of Pennsylvania.
Wed Feb 19, 2014
Valeant Pharmaceuticals PT Raised to $162.00
BMO Capital Markets' price objective indicates a potential upside of 10.60% from the stock's previous close.
Tue Feb 11, 2014
Valeant Pharmaceuticals Sets New 52-Week High at $142.20
Shares of Valeant Pharmaceuticals reached a new 52-week high during trading on Tuesday , AnalystRatingsNetwork reports.
Mon Feb 10, 2014
HAPPI/Household & PP Industry
Valeant To Purchase PreCision Dermatology
More acquisitions are on the way for Valeant Pharmaceuticals International, Inc. The company will acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone.